 - No concurrent medications that may potentially act as modulators of intracellular ceramide levels or ceramide cytotoxicity, sphingolipid transport, or p-glycoprotein MDR1 or MRP1 druglipid transporters, including cyclosporine or analogue, verapamil, tamoxifen or analogue, ketoconazole except if enrolled in group II, chlorpromazine, mifepristone, indomethacin, or sulfinpyrazone 